+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Bevacizumab Biosimilar Market Opportunity, Sales, Price & Clinical Trials Insight 2025

  • ID: 5213965
  • Report
  • December 2020
  • Region: Global
  • 120 Pages
  • Kuick Research
UP TO OFF
until Mar 31st 2021
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Amgen
  • Biothera
  • Centus Biotherapeutics
  • Innovent Biologics
  • Mylan
  • Pfizer
  • MORE

Bevacizumab Biosimilar Market Opportunity, Sales, Price & Clinical Trials Insight 2025 Report Highlights:

  • Bevacizumab Market Opportunity: > USD 12 Billion by 2025
  • Bevacizumab Biosimilar in Clinical Trials: > 25 Biosimilars
  • Bevacizumab Biosimilar Available in Market: >8 Biosimilars
  • Bevacizumab Market Spread: US & Europe Share >  60%
  • Bevacizumab Branded v/s Biosimilar Insight
  • Avastin & Bevacizumab Biosimilar Price, Sales & Dosage Insight
  • Bevacizumab Patent Insight by Indication & Year

Bevacizumab is among the cusp of getting recognized as one of the most prominent drugs for the treatment of multiple types of cancer. Being an innovative approach of immunotherapy capable of neutralizing vascular endothelial growth factor, it got its fast-end approval as a first anti-angiogenic therapy by the regulatory bodies for the benefit of millions of cancer patients. The parent bio-pharmaceutical company of the drug is F. Hoffmann-La Roche AG and in the year 2004, the drug got recognized as one of the promising immunotherapy drugs as a first-line therapy when combined with intravenous 5-fluorouracil-based chemotherapy for the treatment of the patients suffering from metastatic colorectal cancer. Application wise, the drug has extended its wings for the treatment of colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, and ovarian cancer. Such huge segmentation of the global bevacizumab biosimilar drug tends to deliver the large percentage it is contributing to the global cancer biosimilar market.

The emergence of bevacizumab biosimilar drug for the cancer patients have burnt all the issues that were recorded in the past few years i.e. comparison of the biosimilar drugs with the reference drugs. The 20 years of experience of bevacizumab biosimilar drug in the market has achieved high comfort level and rise in overall cancer therapeutics market that was not imagined by the researchers and the patients. The drug market is witnessed to deliver high growing healthcare benefits as the opportunities related with the cancer treatment is apparently more when compared with the treatment expenses of other biological cancer treatments.

The global market of the drug has created a jinxed for the biosimilar market, thus making the researchers and the patients lean towards this mode of treatment as one of the most prominent types. In addition to this, the overall drug market in a very short period of time has come up with high valued and worthy outcome to the parent company and it is seeking towards more robust performance with novel trends in the upcoming years. The market in a very short period of time has been successful in establishing a primary goal for over-shadowing the expensive nature of the cancer treatment towards a novel approach that is cheap, affordable and as beneficial as the reference product.

The analysis of the bevacizumab biosimilar drug performance has landed high market expectations and a classification of the drug market that is 100% accurate in terms of mechanism of action, chemical properties and many more. The association of the market with strong and prominent research team of the parent company is all focused on making the drug as a solo treatment regimen with high quality in combination with other therapies so that all the current challenges could be over-come in short period of time. In addition, it is estimated that the biosimilar drug market of bevacizumab has been able to introduce a unique revolution in the entire biosimilar market, thus resulting in creating a landscape that is successful and central component to trillion dollars cancer therapeutics market.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen
  • Biothera
  • Centus Biotherapeutics
  • Innovent Biologics
  • Mylan
  • Pfizer
  • MORE

1. Bevacizumab - Current Market Overview

2. Bevacizumab - Reimbursement Scenario

3. Bevacizumab - Commercial Availability
3.1 Dosage, Patent & Price Analysis – Branded v/s Biosimilar
3.1.1 Avastin
3.1.2 Mvasi
3.1.3 Zirabev
3.1.4 Aybintio
3.2 Avastin - Sales Analysis

4. Bevacizumab Biosimilar Market Analysis
4.1 Current Market Scenario
4.2 Market Opportunities & Forecast

5. Global Bevacizumab Biosimilar Ongoing Clinical Trials Outlook
5.1 Country
5.2 Indication
5.3 Patient Segment
5.4 Organization

6. Global Bevacizumab Biosimilar Clinical Insight By Phase
6.1 Unknown
6.2 Research
6.3 Preclinical
6.4 Clinical
6.5 Phase-I
6.6 Phase-II
6.7 Phase-II/III
6.8 Phase-III
6.9 Preregistration
6.10 Registered

7. Marketed Bevacizumab Branded & Biosimilar Drug Clinical Insight
7.1 Avastin
7.2 Bevacizumab Biosimilar - KRABEVA
7.3 Bevacizumab Biosimilar - BYVASDA
7.4 Bevacizumab Biosimilar - Bevax
7.5 Bevacizumab Biosimilar - ZIRABEV
7.6 Bevacizumab Biosimilar - Mvasi
7.7 Bevacizumab Biosimilar - Bryxta
7.8 Bevacizumab Biosimilar Bevatas
7.9 Bevacizumab Biosimilar - Cizumab
7.10 Bevacizumab Biosimilar - Versavo
7.11 Bevacizumab Biosimilar - Lumiere

8. Bevacizumab Biosimilar Market - Future Outlook

9. Competitive Landscape
9.1 Amgen
9.2 AryoGen Pharmed
9.3 Biothera
9.4 Boehringer Ingelheim
9.5 Centus Biotherapeutics
9.6 Henlius Biotech
9.7 Innovent Biologics
9.8 Mylan
9.9 mAbxience
9.10 Outlook Therapeutics
9.11 Pfizer
9.12 Prestige Biopharma
9.13 Roche
9.14 Samsung Bio
9.15 TOT Biopharm

List of Figures
Figure 1-1: Global – Bevacizumab Market Size (US$ Billion), 2017 - 2019
Figure 1-2: Global – Bevacizumab Market Opportunity (US$ Billion), 2020 - 2025
Figure 1-3: Bevecezumab – Market Size by Region (%), 2019
Figure 1-4: Bevecezumab – Market Size by Type of Product (%), 2019
Figure 2-1: US – Average Selling Price (ASP) of Bevacizumab Products (US$/10mg), 2020
Figure 2-2: US – Reimbursed Amount of Bevacizumab Products (US$/10mg), 2020
Figure 3-1: Avastin – FDA Approval Year by Indication
Figure 3-2: Avastin – Patent Expiration Year by Region
Figure 3-3: Avastin – Price for a Supply of 4ml & Price per Unit ml Solution for Injection (US$), December’2020
Figure 3-4: Avastin – Price for a Supply of 16ml & Price per Unit ml Solution for Injection (US$), December’2020
Figure 3-5: Avastin – Price for a Supply of 10 & Price for Single 4ml Solution for Injection (US$), December’2020
Figure 3-6: Avastin – Price for a Supply of 10 & Price for Single 16ml Solution for Injection (US$), December’2020
Figure 3-7: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC & Metastatic Cervical Cancer (US$), December’2020
Figure 3-8: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$), December’2020
Figure 3-9: Avastin – Duration of Treatment of Recurrent Glioblastoma & Renal Cell Carcinoma as Combinational & Monotherapy (Weeks), December’2020
Figure 3-10: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$), December’2020
Figure 3-11: Avastin’s Biosimilar - FDA Approval Year
Figure 3-12: Avastin’s Biosimilar - EMA Approval Year
Figure 3-13: Mvasi - Price for 4ml Supply & Price per ml of Intravenous Solution (US$), December’2020
Figure 3-14: Mvasi - Price for 16 ml Supply & Price per Unit of Intravenous Solution (US$), December’2020
Figure 3-15: Zirabev - Price for 4ml Supply & Price per unit of Intravenous Solution (US$), December’2020
Figure 3-16: Zirabev - Price for 16 ml Supply & Price per unit of Intravenous Solution (US$), December’2020
Figure 3-17: Aybintio - Price for 4ml Supply & Price per Unit of Intravenous Solution (GBP/US$), December’2020
Figure 3-18: Aybintio - Price for 16 ml Supply & Price per unit of Intravenous Solution (GBP/US$), December’2020
Figure 3-19: Bevaczumab - Price Comparision for Single Supply of 4 ml Intravenous Solution (US$), December’2020
Figure 3-20: Bevaczumab - Price Comparision for Single Supply of 16 ml Intravenous Solution (US$), December’2020
Figure 3-21: Avastin – Annual Sales Value (US$/CHF Billion), 2017 - 2019
Figure 3-22: Global – Avastin Quarterly Sales Value (US$ Billion), 2018 & 2019
Figure 3-23: US - Avastin Quarterly Sales Value (US$ Million), 2019
Figure 3-24: Avastin – Annual Sales Share by Region (US$ Billion), 2019
Figure 3-25: Avastin – Sales Share by Region (%), 2019
Figure 3-26: Global - Avastin Quarterly Sales Value (US$ Million), Q1 – Q3, 2020
Figure 3-27: Avastin – Sales Share by Region (US$ Billion), Q1 – Q3, 2020
Figure 3-28: Avastin – Sales Share by Region (%), 2019
Figure 4-1: Global – Bevacizumab Biosimilar Market Size by Product (US$ Million), 2019
Figure 4-2: Investigational Bevacizumab Biosimilars & Their Manufacturer
Figure 4-3: Global – Zirabev Market Opportunity (US$ Million), 2019 – 2026
Figure 4-4: Global – Mvasi Market Opportunity (US$ Million), 2019 – 2025
Figure 4-5: US – Mvasi Market Opportunity (US$ Million), 2019 – 2025
Figure 4-6: Global – Bevacizumab Biosimilar Market Opportunity (US$ Billion), 2020 – 2025
Figure 5-1: Global – Bevacizumab Biosimilar Clinical Trials by Country, 2020 – 2025
Figure 5-2: Global – Bevacizumab Biosimilar Clinical Trials by Indication, 2020 – 2025
Figure 5-3: Global – Bevacizumab Biosimilar Clinical Trials by Patient Segment, 2020 – 2025
Figure 5-4: Global – Bevacizumab Biosimilar Clinical Trials by Organization, 2020 – 2025
Figure 6-1: Global – Bevacizumab Biosimilar Clinical Trials by Phase, 2020 – 2025
Figure 6-2: Global – Bevacizumab Biosimilar Clinical Trials by Phase, 2020 – 2025

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Amgen
  • AryoGen Pharmed
  • Biothera
  • Boehringer Ingelheim
  • Centus Biotherapeutics
  • Henlius Biotech
  • Innovent Biologics
  • Mylan
  • mAbxience
  • Outlook Therapeutics
  • Pfizer
  • Prestige Biopharma
  • Roche
  • Samsung Bio
  • TOT Biopharm
Note: Product cover images may vary from those shown
Adroll
adroll